Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BUCET vs ALLZITAL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Bucet is a combination of bucetin and acetaminophen. Bucetin is a para-aminophenol derivative with analgesic and antipyretic effects, possibly through inhibition of cyclooxygenase in the central nervous system. Acetaminophen inhibits COX enzymes in the brain, reducing prostaglandin synthesis and fever.
Allzital contains phenobarbital, a barbiturate that enhances GABA-A receptor activity by increasing the duration of chloride ion channel opening, leading to neuronal hyperpolarization and inhibition of neurotransmission.
Management of mild to moderate pain,Reduction of fever
Sedation,Short-term treatment of insomnia,Management of seizure disorders (generalized tonic-clonic and partial seizures),Preoperative anxiety
Oral: 25-50 mg every 4-6 hours as needed for pain; maximum 200 mg/day.
5-10 mg orally every 4-6 hours as needed for pain; not to exceed 40 mg per day.
2-4 hours (terminal); prolonged in renal impairment
Terminal elimination half-life is 4-6 hours in healthy adults; prolonged to 8-12 hours in renal impairment.
Bucetin: Hepatic metabolism via hydroxylation and glucuronidation. Acetaminophen: Hepatic metabolism via glucuronidation, sulfation, and CYP2E1-mediated oxidation to NAPQI.
Primarily hepatic via CYP2C9, CYP2C19, and glucuronidation; metabolized to inactive metabolites (e.g., p-hydroxyphenobarbital) that are excreted renally.
Renal: ~70% unchanged; biliary/fecal: ~30% as metabolites
Renal: 70% as unchanged drug; biliary/fecal: 20% as metabolites; 10% other.
~85% bound to albumin
92% bound to albumin and alpha-1-acid glycoprotein.
0.3-0.5 L/kg; distributes primarily into extracellular fluid
2.5-3.5 L/kg; large Vd indicates extensive tissue distribution.
Oral: 75-90%
Oral: 85-90% due to first-pass metabolism; intravenous: 100%.
GFR 10-50 m L/min: 50% dose reduction; GFR <10 m L/min: avoid use.
GFR 30-50 m L/min: 50% dose reduction; GFR <30 m L/min: avoid use.
Child-Pugh A: no adjustment; Child-Pugh B: 50% dose reduction; Child-Pugh C: avoid use.
Child-Pugh Class B: 50% dose reduction; Child-Pugh Class C: avoid use.
Children 6-12 years: 5 mg/kg/dose every 6 hours as needed; maximum 20 mg/kg/day.
0.1-0.2 mg/kg orally every 4-6 hours as needed; maximum single dose 5 mg; not to exceed 20 mg per day.
Start at lowest effective dose (12.5 mg every 6 hours); maximum 150 mg/day due to increased fall risk and renal impairment.
Initiate at 2.5 mg orally every 6 hours; titrate cautiously due to increased sensitivity and risk of respiratory depression.
No FDA black box warnings for bucet. Acetaminophen component: Risk of severe liver injury at high doses or with alcohol use.
Risk of respiratory depression, particularly with rapid IV administration or excessive doses; co-administration with CNS depressants (e.g., opioids, alcohol) may exacerbate this effect. Use in pregnancy may cause fetal harm (teratogenic effects).
Hepatotoxicity risk with acetaminophen overdose,Avoid alcohol use,Hypersensitivity reactions,Skin reactions (Stevens-Johnson syndrome)
Respiratory depression, CNS depression, dependence and withdrawal (taper gradually), paradoxical excitation (especially in elderly), use in hepatic or renal impairment, drug interactions with warfarin, oral contraceptives, and corticosteroids.
Severe hepatic impairment,Hypersensitivity to bucetin or acetaminophen
Hypersensitivity to barbiturates, severe respiratory insufficiency, history of porphyria, severe hepatic impairment, pregnancy (especially first trimester).
No known food interactions. Avoid alcohol as it may increase risk of side effects like dizziness.
Avoid excessive alcohol consumption; may increase hepatotoxicity. No significant food interactions. Take with or without food; food may reduce GI upset.
FDA Pregnancy Category D. First trimester: Increased risk of cardiac malformations and neural tube defects. Second and third trimesters: Risk of premature closure of ductus arteriosus, oligohydramnios, and neonatal renal impairment.
Allzital (butalbital/acetaminophen/caffeine) is category C. First trimester: risk of neural tube defects increased with barbiturate exposure; avoid. Second/third trimester: barbiturate use may lead to neonatal withdrawal and coagulation defects due to vitamin K deficiency; use only if benefit outweighs risk.
Contraindicated. Excreted in human milk; M/P ratio not established. Potential for serious adverse effects in nursing infant.
Butalbital and acetaminophen are excreted into breast milk in low amounts. Caffeine also enters milk. M/P ratio not established for butalbital. Use caution; monitor infant for sedation, poor feeding. American Academy of Pediatrics considers butalbital compatible with breastfeeding but avoid prolonged use.
Avoid use during pregnancy. If unavoidable, reduce dose by 50% due to increased clearance and altered protein binding.
No specific dose adjustments established for pregnancy. Pharmacokinetic changes (increased volume of distribution, hepatic metabolism) may reduce butalbital levels; clinical efficacy not well studied. Use lowest effective dose shortest duration. Acetaminophen doses remain standard (<4 g/day). Avoid caffeine >300 mg/day.
Bucet (bupivacaine hydrochloride and epinephrine) is used for local anesthesia. Epinephrine prolongs anesthetic effect and reduces systemic absorption. Avoid in patients with severe hypertension, hyperthyroidism, or concurrent MAO inhibitors. Monitor for CNS and cardiac toxicity, especially with high doses. Epinephrine concentration is 1:200,000; check for allergy to sulfites (antioxidant).
ALLZITAL is a combination analgesic containing acetaminophen and tramadol. Monitor for serotonin syndrome when used with other serotonergic drugs. Avoid in patients with severe hepatic impairment or acute alcohol intoxication. Maximum daily acetaminophen dose is 4000 mg; reduce in hepatic risk. Tramadol may lower seizure threshold; use cautiously in epilepsy. Not recommended in breastfeeding due to tramadol excretion. Adjust dose in renal impairment (Cr Cl <30 m L/min: extended interval). Discontinue gradually to avoid withdrawal.
Do not drive or operate machinery until numbness subsides.,Avoid touching or scratching the numb area to prevent injury.,Report any signs of allergic reaction (rash, swelling, difficulty breathing) or intravenous injection symptoms (rapid heart rate, anxiety, headache).,The numbness will wear off over several hours depending on the dose and site.
Do not exceed 8 tablets per day due to acetaminophen liver risk.,Avoid alcohol and other acetaminophen-containing products.,May cause dizziness or drowsiness; avoid driving until effect known.,Report signs of serotonin syndrome (agitation, hallucinations, rapid heart rate).,Do not stop suddenly; taper to prevent withdrawal symptoms.,Store at room temperature away from moisture.,Use only as prescribed; risk of dependence with tramadol.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BUCET vs ALLZITAL, answered by our medical review team.
BUCET is a Barbiturate Combination Analgesic that works by Bucet is a combination of bucetin and acetaminophen. Bucetin is a para-aminophenol derivative with analgesic and antipyretic effects, possibly through inhibition of cyclooxygenase in the central nervous system. Acetaminophen inhibits COX enzymes in the brain, reducing prostaglandin synthesis and fever.. ALLZITAL is a Barbiturate Analgesic Combination that works by Allzital contains phenobarbital, a barbiturate that enhances GABA-A receptor activity by increasing the duration of chloride ion channel opening, leading to neuronal hyperpolarization and inhibition of neurotransmission.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BUCET and ALLZITAL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BUCET is: Oral: 25-50 mg every 4-6 hours as needed for pain; maximum 200 mg/day.. The standard adult dose of ALLZITAL is: 5-10 mg orally every 4-6 hours as needed for pain; not to exceed 40 mg per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BUCET and ALLZITAL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BUCET is classified as Category C. FDA Pregnancy Category D. First trimester: Increased risk of cardiac malformations and neural tube defects. Second and third trimesters: Risk of premature closure of ductus arterio. ALLZITAL is classified as Category C. Allzital (butalbital/acetaminophen/caffeine) is category C. First trimester: risk of neural tube defects increased with barbiturate exposure; avoid. Second/third trimester: barbitu. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.